Journals / Nöropsikiyatri Arşivi / 2017 / Cilt: 54 - Sayı: 4

Validity and Reliability of the Turkish Version of the Multiple Sclerosis- Related Symptom Checklist

Pages
328–333
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The Turkish version of MS-RS is a valid and reliable scale that can be used in the Turkish population.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Multiple sclerosis (MS) is a disease that causes different symptoms in each attack and has an individual-specific course.
📊
Key Findings & Data:Methods: The study was conducted in the outpatient MS clinic of the Istanbul University Istanbul Faculty of Medicine between January and October 2013 and included a sample group of 148 patients who were aged >18 years, could easily communicate, had a definite diagnosis of MS, and had no other medical problems besides MS.
💡
Conclusion & Impact:Conclusion: The Turkish version of MS-RS is a valid and reliable scale that can be used in the Turkish population.
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: Multiple sclerosis (MS) is a disease that causes different symptoms in each attack and has an individual-specific course. Detailed questioning and recording of MS symptoms is important for developing a management plan for individual-specific symptoms. The present study was planned to evaluate the validity and reliability of the Turkish version of “Multiple Sclerosis-Related Symptom Checklist” (MS-RS), which has been developed for patients to personally followup the symptoms they experience. Methods: The study was conducted in the outpatient MS clinic of the Istanbul University Istanbul Faculty of Medicine between January and October 2013 and included a sample group of 148 patients who were aged >18 years, could easily communicate, had a definite diagnosis of MS, and had no other medical problems besides MS. The data were collected using patient information forms, including sociodemographic and MS-RS forms. To assess the linguistic validity, the Likert-type scale with 26 items was first applied to a group of 30 patients. Confirmatory factor analysis was used to test the construct validity. Furthermore, the correlation of the scale with the Expanded Disability Status Scale (EDSS), Hospital Anxiety and Depression Scale (HADS), Mini-Mental Status Evaluation (MMSE) scale, and Multiple Sclerosis Quality of Life Scale-54 (MSQL-54) was evaluated. Results: The scale comprised five factors with factor loading values between 0.39 and 0.86. The item-total correlation coefficients revealed values of 0.27–0.88. The Cronbach’s alpha reliability coefficient for the whole scale was determined to be 0.89 and for the subscales to be 0.60–0.85. The test–retest analysis revealed no difference between the scale and its subscales in terms of invariance with time (p>0.05). Moreover, MS-RS was significantly correlated with EDSS, HADS, MMSE, and MSQL-54. Conclusion: The Turkish version of MS-RS is a valid and reliable scale that can be used in the Turkish population.

🔖

Cite This Article

TÜLEK, Z., POLAT, C., KÜRTÜNCÜ, M., ERAKSOY, M. (2017). Validity and Reliability of the Turkish Version of the Multiple Sclerosis- Related Symptom Checklist. Nöropsikiyatri Arşivi, Cilt: 54 - Sayı: 4, 328–333. https://ajindex.com/articles/292319

References (14)

  1. Compston A, Coles A. Multiple sclerosis [seminar]. Lancet 2008
  2. [CrossRef] 2. Goodin DS. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol 2014
  3. [CrossRef] 3. Melcon MO, Correale J, Melcon CM. Is it time for a new global classification of multiple sclerosis? J Neurol Sci 2014
  4. [CrossRef] 4. Heydarpour P, Khoshkish S, Abtahi S, Moradi-Lakeh M, Sahraian MA. Multiple Sclerosis Epidemiology in Middle East and North Africa: A Systematic Review and Meta-Analysis. Neuroepidemiology 2015
  5. [CrossRef] 5. Feinstein A, DeLuca J, Baune BT, Filippi M, Lassman H. Cognitive and neuropsychiatric disease manifestations in MS. Mult Scler Relat Disord 2013
  6. [CrossRef] 6. Hickman SJ, Raoof N, McLean RJ, Gottlob I. Vision and multiple sclerosis. Mult Scler Relat Disord 2014
  7. [CrossRef] 7. Patti F, Vila C. Symptoms, prevalence and impact of multiple sclerosis in younger patients: a multinational survey. Neuroepidemiology 2014
  8. [CrossRef] 8. Shahrbanian S, Duquette P, Kuspinar A, Mayo NE. Contribution of symptom clusters to multiple sclerosis consequences. Qual Life Res 2015
  9. [CrossRef] 9. Newland PK, Lorenz R, Budhathoki C, Jensen MP. The presence of symptoms with comorbid conditions in individuals with multiple sclerosis (MS) Clin Nurs Res 2015. pii: 1054773815592817. 10. Tabrizi FM, Radfar M. Fatigue, sleep quality, and disability in relation to quality of life in multiple sclerosis. Int J MS Care 2015
  10. [CrossRef] 11. Henze T, Rieckmann P, Toyka KV. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol 2006
  11. [CrossRef] 12. de Sa JC, Airas L, Bartholome E, Grigoriadis N, Mattle H, Oreja-Guevara C, O’Riordan J, Sellebjerg F, Stankoff B, Vass K, Walczak A, Wiendl H, Kieseier BC. Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord 2011
  12. [CrossRef] 13. Newland PK, Flick LH, Thomas FP, Shannon WD. Identifying symptom co-occurrence in persons with multiple sclerosis. Clini Nurs Res 2014
  13. [CrossRef] 14. Gupta S, Goren A, Phillips AL, Dangond F, Stewart M. Self-reported severity among patients with multiple sclerosis in the U.S. and its association with health outcomes. Mult Scler and Relat Disord 2014
  14. [CrossRef] 15. Motl RW, Snoo